Stock Evaluator: VolitionRx Limited (VNRX)

VolitionRx Limited VNRX

$0.31 -0.03 -8.76%
September 11, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,050,017
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD AMEX | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Commentary & Analysis


Financial Summary

Share Statistics VNRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $4.4 $385.8 3%
Shares Out (Mil) 9.2 40.8 20%
Institutional Ownership 84.5% 83.6% 52%
Float (Mil) 12.5 34.7 22%
Beta 1.09 0.88 65%
Avg Daily Volume (000s) 3,388 291 90%
Price Change
(52-week)
(97.5%) 61.6% 2%
Growth VNRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 11.8% na
Net Income (5yr) (2.8%) (5.8%) 36%
EPS (5yr) 13.4% 10.4% 53
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (18.8%) (15.5%) 36%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 1 1 1
Current EPS ($0.310) ($2.000) ($0.850)
Month Ago EPS ($0.580) ($2.620) ($1.150)
# Rev Up 0 1 0
# Rev Down 1 0 1
Three Months Ago EPS ($0.580) ($2.620) ($1.150)
Year/Year Chg (63.5%) (54.3%) (91.3%)
Financials VNRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $3 $119 4%
Net Income (TTM) (Mil) ($26) ($9) 22%
EPS (TTM) ($3.804) ($0.400) 9%
Operating Cash Flow (TTM) (Mil) ($20) ($3) 15%
Net Cash Flow (TTM) (Mil) $1 $1 44%
Long-Term Debt (Q1) (Mil) $7 $23 26%
Enterprise Value (Q1) (Mil) $12 $371 8%
Valuation VNRX Industry
Median
Percentile
(All Stocks)
P/B na 2.74 na
P/E na 25.1 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.5 na
Ratios VNRX Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 58.3% 96%
Net Margin na (6.9%) na
ROA (301.5%) (12.7%) 1%
ROE 80.1% (12.3%) 95%
Liabilities to Assets 504.0% 46.0% 100%
F-Score 3 4 18%

VolitionRx Limited did not pass any screens on 9/11/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors